Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study (Q56778458)
Jump to navigation
Jump to search
article by Denis C Talbot et al published 15 December 2010 in Clinical Cancer Research
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study |
article by Denis C Talbot et al published 15 December 2010 in Clinical Cancer Research |
Statements
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study (English)
0 references
15 December 2010
0 references
16
0 references
24
0 references
6150-8
0 references